Close

Wedbush Cuts Price Target on United Therapeutics (UTHR) as Launch Timing Becomes Unclear for Remodulin Implantable Pump

March 24, 2016 2:07 PM EDT Send to a Friend
Wedbush maintained an Outperform rating on United Therapeutics Corp. (NASDAQ: UTHR), and cut the price target to $229.00 (from $238.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login